Related Experiment Video
Updated: Jan 3, 2026

Guidelines for Elective Pediatric Fiberoptic Intubation
Published on: January 17, 2011
Caffeine treatment for bronchiolitis-related apnea in the pediatric intensive care unit
N Heuzé1, I Goyer2, F Porcheret3
1CHU de Caen, Pediatric Intensive Care Unit, 14000, Caen, France; CHU de Caen, Pediatric Emergency Department, 14000, Caen, France; CH de Lisieux, Department of Pediatrics, 14000, Lisieux, France.
Insights
Caffeine treatment for bronchiolitis-related apnea (BRA) is common in pediatric intensive care units (PICUs), but this study found no significant clinical benefits or adverse effects. Further research is needed to determine optimal dosing for this population.
Area of Science:
- Pediatric Critical Care Medicine
- Neonatal and Developmental Medicine
Background:
- Apnea is a frequent complication in infants diagnosed with bronchiolitis.
- Current management guidelines for bronchiolitis-related apnea (BRA) are lacking.
- Pediatric intensive care unit (PICU) practitioners often use caffeine, extrapolating from prematurity-related apnea protocols.
Purpose of the Study:
- To describe BRA management practices within a specific PICU.
- To determine the rate of caffeine prescription for BRA.
- To explore the impact of caffeine on clinical outcomes in infants with BRA.
Main Methods:
- A retrospective study was conducted in a university hospital PICU from 2009 to 2016.
- Infants under one year old diagnosed with BRA were included.
- Patients were categorized into a control group or a caffeine group based on treatment.
Main Results:
- Out of 54 infants, 91% received caffeine treatment.
- Ventilatory support was required for 93% of patients.
- No significant differences in supportive care or PICU length of stay were observed between groups.
- Caffeine administration was not linked to adverse events.
Conclusions:
- Caffeine administration for BRA appears to be a localized standard practice.
- The study was underpowered to demonstrate clinical benefits of caffeine for BRA.
- Caffeine treatment showed no significant adverse effects in this cohort.
- Optimal caffeine dosing for BRA in postterm infants requires further investigation.
Introduction:
Apnea is commonly encountered in children with bronchiolitis. Despite the lack of recommendations regarding bronchiolitis-related apnea (BRA) management, some pediatric intensive care unit (PICU) practitioners use caffeine treatment based on extrapolation from the recommendations for prematurity-related apnea management. The objectives of this study were to describe the management of BRA in our PICU, evaluate the caffeine prescription rate for this indication, and explore its potential effects on clinical outcomes.
Methods:
This was a retrospective study in a university hospital PICU between January 1st, 2009 and December 31st, 2016. All children under 1 year of age admitted to the PICU with a diagnosis of BRA were included. Patients were allocated to a control group or a caffeine group depending on the administration of caffeine.
Results:
In total, 54 infants were included and caffeine treatment was administered to 49 (91%) of them. Patient characteristics were similar between the two groups. Ventilatory support was initiated for 50 patients (93%). Supportive care and length of PICU stay were similar between the two groups. Caffeine was not associated with adverse events.
Conclusion:
Caffeine treatment in BRA could be considered as a local standard practice. This retrospective study was underpowered to show any benefit of caffeine treatment on clinical outcomes. This treatment was not associated with significant adverse effects. We raised the question of the appropriate caffeine dosing regimen for BRA in this postterm population. Further studies on this topic are warranted.
Related Concept Videos
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Cardiopulmonary Resuscitation II: ACLS Airway Management
Acute Respiratory Failure-III
Pulmonary Cycle: Exhalation
COPD: Management Using Bronchodilators and Corticosteroids
Pharmacokinetics in Pediatric Patients: Drug Excretion

